title: Measles control in developing and developed countries: the case for a two-dose policy.
abstract: Despite major reductions in the incidence of measles and its complications, measles control with a single dose of the currently used. Schwarz strain vaccine has failed to eradicate the disease in the developed countries. In developing countries an enormous toll of measles deaths and disability continues, despite considerable efforts and increasing immunization coverage. Empirical evidence from a number of countries suggests that a two-dose measles vaccination programme, by improving individual protection and heard immunity can make a major contribution to measles control and elimination of local circulation of the disease. Cost-benefit analysis also supports the two-dose schedule in terms of savings in health costs, and total costs to society. A two-dose measles vaccination programme is therefore an essential component of preventive health care in developing, as well as developed countries for the 1990s.
authors.affiliation: Preventive Health Services, Ministry of Health, Jerusalem, Israel.
authors.forename: T H
authors.initials: TH
authors.lastname: Tulchinsky
authors.forename: G M
authors.initials: GM
authors.lastname: Ginsberg
authors.forename: Y
authors.initials: Y
authors.lastname: Abed
authors.forename: M T
authors.initials: MT
authors.lastname: Angeles
authors.forename: C
authors.initials: C
authors.lastname: Akukwe
authors.forename: J
authors.initials: J
authors.lastname: Bonn
mesh_terms: D003362:Cost-Benefit Analysis; D003906:Developing Countries; D005060:Europe; D005102:Health Expenditures; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D008457:Measles / Q000191:economics / Q000517:prevention & control*; D008458:Measles Vaccine / Q000008:administration & dosage*; D014481:United States
chemical_list: D008458:Measles Vaccine